Gregory Renza

“Guys, just with respect to some of the R&D efforts that you've discussed about potentially looking externally, namely the PanRAS ADC portfolio as well as VW191, just provide some updates of how that's either going to be accelerated or how you're evolving the framework with which you want to take that forward with…”

“Greg, good morning, and thank you, Asantecine, for taking my question, and congrats on the progress. My question, just to start, is just on the septiclax. Certainly, when it comes to the commercial trajectory over this year, Could you just comment about how that's perhaps changed since Sonro has entered the market?”

“Greg, good morning, and thank you, Asantecine, for taking my question, and congrats on the progress. My question, just to start, is just on the septiclax. Certainly, when it comes to the commercial trajectory over this year, Could you just comment about how that's perhaps changed since Sonro has entered the market?”

“I guess originally when you guys designed that protocol and had assumptions for that frontline study, is the timing of the readout, you know, fourth quarter more so in line with what you guys originally modeled when you first started the study?”

“David, maybe just to follow up on the GSK approval and launch, talked about some of the, maybe the surprises and just the positioning with the TROZI now against the latest entrant.”